Radiopharmaceutical programs depend on evidence about targeting: whether a probe reaches its target in a living system, where else it distributes, and how confidently the imaging signal can be interpreted.
Research areas
From probe to interpretable evidence
- Probe research — design considerations linking the probe to the biological target and question.
- Radiolabeling — labeling strategy, quality checks, and stability evaluation.
- Biodistribution — tissue distribution and time-course measurement in preclinical systems.
- Quantitative imaging — imaging studies designed for measurement, not illustration.
- Experimental assessment — findings interpreted with molecular and pharmacokinetic evidence.
Scope and limitations
Scope: This is preclinical research support. It does not imply clinical manufacturing, GMP production, or approved diagnostic capability, and an imaging signal alone does not prove intact drug distribution or therapeutic effect. Feasibility depends on the candidate, target, model, probe, and instrument availability. Delivery is coordinated with participating research organizations with the relevant facilities, including ImageNova for preclinical imaging — a separate legal entity.
Relevant capabilities: Preclinical Imaging and Translational Evidence.
Developing a targeted radiopharmaceutical?
Tell us about the probe, the target, and the evidence you need.